Hanson Wade’s Post

Prospection's patient-centric intelligence (#PCI) helped J&J Innovative Medicine Asia Pacific uncover important real-world patient insights on endothelin receptor antagonist (ERA) persistence in pulmonary arterial hypertension (PAH) in Japan. Find out how PCI can illuminate the patient journey and ultimately deliver improved outcomes for patients as well as pharma teams.  🟢 Read the full research publication 👉  https://lnkd.in/gjGpt4TJ

#ACROHighlights [Featured Product] 🚀 Harnessing Cardiac Organoids for Enhanced Drug Development 🌟 Drug-induced cardiotoxicity is a significant challenge in new drug development. Due to their physiological relevance and reproducibility, cardiac organoids derived from iPSCs are now a game-changer for high-throughput drug safety screening. At ACROBiosystems, we've developed cardiac organoids that accurately predict drug-induced cardiotoxicity. But we don't stop there! Our ongoing research also covers other organoid models, including brain, liver, and intestines, to offer comprehensive support for future clinical trials. Join us at the forefront of innovation in drug development! 💊✨ 🔗https://lnkd.in/gzPuS_xg #Biotech #DrugDevelopment #Organoids #iPSCs #AllianzBioinnovation #Research #India #ACROBiosystems

In PK studies, special administration methods may increase drug concentration in the target tissue, enhance therapeutic effects, or reduce the incidence of adverse reactions. Yufeng Meng, the Assistant Director of #DMPK at Medicilon, provides insights on the techniques and applications of target organ biopsy in PK studies. This information aims to help reduce confusion and challenges in #PK trials.

Johnson & Johnson's experimental autoimmune drug, nipocalimab, demonstrated success in a Phase 3 study for treating generalized myasthenia gravis, offering significant benefits compared to a placebo. The drug works by targeting disease-causing antibodies, leading to improved daily functioning and quality of life for patients. J&J is optimistic about the potential approval of nipocalimab for this condition and aims to expand its usage across multiple indications, projecting substantial revenue growth. #AutoimmuneDisease #Nipocalimab #MyastheniaGravis #AntibodyTherapy #HealthcareInnovation Read more here: https://lnkd.in/egiNWQNN BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

In PK studies, special administration methods may increase drug concentration in the target tissue, enhance therapeutic effects, or reduce the incidence of adverse reactions. Yufeng Meng, the Assistant Director of #DMPK at Medicilon, provides insights on the techniques and applications of target organ biopsy in PK studies. This information aims to help reduce confusion and challenges in #PK trials.

The conviction that #serendipity can be, if not systematized, at least harnessed for augmented scientific discovery, has fueled my (obviously nonlinear) professional trajectory. As we saw with Fleming's "accidental" discovery of penicillin, the #AHA moment does not happen in a vacuum: the mind needs to be ready for the discovery (or "pasteurized" for chance to favor you). While researching other examples of serendipitous drug discovery, I came across an article about systematizing serendipity for cardiovascular drug discovery. It does not fully deliver on its promise, but I can't resist sharing that it is published in AHA journals. In case you are wondering, AHA is the American Heart Association. https://lnkd.in/gWhy2fUS

🧬✨ Investigating the safety and effectiveness of a new drug combination for treating recurrent high-grade #Astrocytomas: A phase 1 clinical trial. 🧬✨ Astrocytoma is a type of brain tumor that originates from star-shaped glial cells in the brain called astrocytes. According to the WHO classification, they are classified into four grades based on the degree of malignancy and aggressiveness. Pilocytic astrocytoma and diffuse astrocytoma are considered low-grade astrocytomas, while anaplastic astrocytoma and glioblastoma multiforme are considered high-grade astrocytomas. High-grade astrocytomas are difficult to treat due to their aggressive nature and resistance to therapy. 🧠💊 This study contributes to the ongoing research on treatment options for malignant astrocytomas, specifically glioblastoma, and anaplastic astrocytoma. The combination of zotiraciclib with temozolomide, a standard chemotherapy drug, shows promising results regarding safety and tolerability. 💪❤️ For more details, watch our video @ https://lnkd.in/gcMyQzV7 and learn more about this groundbreaking trial and its potential to transform astrocytoma treatment. #CancerResearch #ClinicalTrials #BrainTumor #MedicalInnovation #Astrocytoma #Hope #Science #Medicine #Healthcare #Research #Breakthroughs #AstrocytomaSymptoms #AstrocytomaGrade2 #AstrocytomaGrade3 #AstrocytomaGrade4 #AstrocytomaPrognosis #AstrocytomaGrade1 #TypesOfAstrocytoma #AstrocytomaSymptoms #India #CellTalk #LifeScinces #Journal #HealthJournal #JournalClub #Healthcare #YouTube 

This Friday an FDA advisory committee will meet to discuss the results of a new meta-analysis on the use of minimal residual disease (MRD) as an endpoint to support the accelerated approval of new drugs in multiple myeloma (MM). Currently, drugs in MM are approved based on clinical benefit endpoints, leading to lengthy clinical trials and drug approval timelines and ultimately delays in offering patients potentially beneficial treatments. MRD testing can measure a patients response to treatment by the use of sensitive technologies which measure the level of tumor cells in a patient’s blood. The use of MRD results as an endpoint for drug approval would allow MRD testing to be used to demonstrate drug efficacy instead of clinical response thus shortening clinical trial and drug development times. A recent Diaceutics report on the use and perceptions of MRD found the majority of hematoncologists were comfortable with the use of MRD as a surrogate endpoint in clinical trials. If implemented, this would represent a paradigm shift in the approval of novel therapies. While this discussion is currently limited to MM, the scope for using MRD in drug development and the management of patients is currently being investigated in multiple haematological and solid tumor indications. MRD has the potential to become routine clinical practice in the management of oncology indications and would enable the early detection of disease relapse and allow patient treatments to be adapted accordingly. View the Diaceutics report on MRD at https://lnkd.in/eKu4imxW

Breakthrough approach on MRD which could significantly impact timelines on getting new treatments to patients. If you have not accessed the Diaceutics report on MRD read more at the link below and get in touch. Dr Bob Holt #precisionmedicine #patients #FDA #MRD #cancer

🔬 Dive deep into the world of central nervous system (CNS) therapies with our Chief Scientist, francesca cormack! Join us in partnership with Altasciences as we unravel the critical stages of drug development for CNS-active compounds. Sign up here: https://lnkd.in/eMRuh5Xc 💡 In this exclusive webinar, we'll uncover: - Determining the essential cognitive and pharmacodynamic tests crucial for your new CNS-active drug. - Identifying the most relevant and valid populations for testing, ensuring precision in your research. - Leveraging cognitive and pharmacodynamic data effectively for seamless drug development and regulatory planning. Sign up today to hear from some of the brightest minds in CNS research: https://lnkd.in/eMRuh5Xc #CNS # webinar #digitalbiomarkers #cognitivetesting